The study the effectiveness of the combined enterosorbent based on calcium hydroxyapatite in eimeriosis treatment

Introduction. Protozoal intestinal infections are quite common in the modern world. They cause severe clinical manifestations, and in some cases, more often, in countries with a hot climate, lead to death. This is due to the ability of the pathogen to enter the human body through water, fecal-oral or alimentary routes. In this regard, the development of a new safe and effective enterosorbent for protozoal diseases affecting the gastrointestinal tract is relevant.Aim: To study the effectiveness of the combined enterosorbent based on hydroxyapatite and compare the effectiveness of its use with colloidal silicon dioxide (Polysorb) in relation to protozoa (eimeria) in an experiment on rabbits.Material and Methods. The development of a combined enterosorbent based on calcium hydroxyapatite and experimental treatment of laboratory animals (rabbits - 40 animals) infected with protozoal disease - eimeriosis was carried out. Four groups were formed: healthy control, infected control, infected experimental group, infected comparison group (comparison drug - Polysorb). The therapy was carried out for 5 days. The drugs were administered orally.Results. It is shown that the use of a combined enterosorbent based on calcium hydroxyapatite in a daily dose of 0.05 g per 1 kg of body weight led to a decrease in the intensity of invasion of the gastrointestinal tract of rabbits by oocysts by 80% compared with the control, and the use of colloidal silicon dioxide in a daily dose of 0.1-0.2 g per 1 kg of body weight by 49% compared with control.Conclusion. The combined preparation based on calcium hydroxyapatite effectively reduces the intensity of invasion by oocysts of the gastrointestinal tract of rabbits in the experiment. Its intensity efficiency exceeds the intensity of colloidal silicon dioxide by 31%.